HCC

Oncology·MeSH: Adenomatous Polyposis Coli

Prevalence

30.0 / 100K

20 drugs in development·16 companies·3 clinical trials

Drug Pipeline by Phase

Approved(3)

Phase 3(3)

Drug	Company
amezalpat	Tempest Therapeutics, Inc. (TPST)
Pumitamig	BRISTOL MYERS SQUIBB CO (BMY)
tpst-1120	Tempest Therapeutics, Inc. (TPST)

Phase 2(7)

Drug	Company
Branched-Chain Amino Acids	ENANTA PHARMACEUTICALS INC (ENTA)
CTLA-4 Antibody	Crinetics Pharmaceuticals, Inc. (CRNX)
incb062079	Incyte Corp. (INCY)
Lenvatinib	ENANTA PHARMACEUTICALS INC (ENTA)
mFOLFOX/FOLFIRI	KYNTRA BIO INC. (KYNB)
Rencofilstat (formerly CRV431; CPI-431-32)	Hepion Pharmaceuticals, Inc. (CTRVP)
rencofilstat (formerly CRV431)	Hepion Pharmaceuticals, Inc. (CTRVP)

Phase 1(3)

Drug	Company
afp-tcr-t	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
Monoclonal antibody BAT6026	Crinetics Pharmaceuticals, Inc. (CRNX)
sn301a	Senti Biosciences, Inc. (SNTI)

Preclinical(1)

Drug	Company
mipsagargin	REBUS HOLDINGS, INC. (NSPX)

Phase 1/Phase 2(3)

Drug	Company
otx-2002	Omega Therapeutics, Inc. (OMGA)
ryz801	RayzeBio, Inc. (RYZB)
will receive hh-009	China Health Industries Holdings, Inc. (CHHE)

BioSniper tracks 20 drugs in development for HCC across 16 companies.

There are 3 clinical trials targeting HCC tracked by BioSniper.

The estimated prevalence of HCC is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.